BridGene Biosciences utilizes its proprietary IMTAC™ platform, which combines covalent chemistry and quantitative mass spectrometry, to screen small molecules against the entire proteome in live cells. This approach targets approximately 90% of disease-associated proteins that lack known binding sites, enabling the discovery of therapeutic candidates for previously undruggable targets.
Funding
$50.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
LCFounders
Product
Problem
Approximately 90% of disease-associated proteins are considered "undruggable" due to the absence of known binding sites, hindering the development of effective therapies for numerous diseases. Traditional drug discovery methods struggle to identify small molecules that can bind to and modulate these challenging targets.
Solution
BridGene Biosciences addresses the challenge of undruggable targets with its proprietary IMTAC™ (Isobaric Mass Tagged Affinity Characterization) platform. This chemoproteomics platform combines covalent chemistry, live-cell screening, and quantitative mass spectrometry to screen small molecules against the entire proteome in live cells. IMTAC™ identifies novel drug candidates by discovering how small molecules interact with previously inaccessible regions of disease-causing proteins. This approach enables the development of innovative small molecule drugs that can target high-value, yet previously undruggable, targets, offering new therapeutic avenues for diseases with unmet medical needs.
Target Audience
The primary audience includes pharmaceutical companies, research institutions, and drug developers seeking to discover novel therapeutic targets and develop innovative small molecule drugs for previously undruggable targets.
Features
- IMTAC™ platform enables proteome-wide screening in live cells to identify novel drug targets.
- Utilizes a well-designed covalent small molecule library to target diverse amino acids.
- Employs quantitative mass spectrometry to identify and quantify protein-small molecule interactions.
- Facilitates target-focused screening against high-value targets, including oncogenic mutants.
- Allows screening in different cellular states by applying various stimuli to cells.
- Identifies both covalent and non-covalent interacting proteins.
- Can screen in different cellular compartments for maximal proteomic coverage.